Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmadrug Inc C.PHRX

Alternate Symbol(s):  LMLLF

Medical Care Cannabis
PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled-substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural... see more

Recent & Breaking News (CSE:PHRX)

PharmaDrug Inc. Enters Definitive Agreement to Acquire SecureDose Synthetics

Newsfile October 27, 2023

PharmaDrug Announces Share Consolidation and Change to Chief Financial Officer

Newsfile October 20, 2023

PharmaDrug Announces Amendment to Shareholder Meeting Matter

Newsfile September 19, 2023

PharmaDrug Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease

Newsfile September 14, 2023

PharmaDrug Announces Appointment of CEO and Changes to the Board of Directors

Newsfile September 6, 2023

PharmaDrug Announces Strategic Investment in Sairiyo Therapeutics Inc.

Newsfile July 18, 2023

PharmaDrug Announces Termination of General Security Agreement and Issuance of Common Shares

Newsfile July 5, 2023

PharmaDrug Brings On Advisor to Maximize Shareholder Value With Its Underlying Assets

Newsfile May 23, 2023

CSE Bulletin: Reinstatement - Pharmadrug Inc. (PHRX)

Newsfile May 17, 2023

IIROC Trade Resumption - PHRX

Canada NewsWire May 17, 2023

CSE Bulletin: Suspensions - AOC, BHNG, LQID, PKB, PHRX, PLAY, SHFT, SOLV, SPO, TNY, WIB, YOOM

Newsfile May 8, 2023

PharmaDrug Announces Cease Trade Order

Newsfile May 8, 2023

IIROC Trading Halt - PHRX

Canada NewsWire May 8, 2023

PharmaDrug Announces Non-Brokered Offering of $100,000 of Convertible Secured Debentures

Newsfile April 14, 2023

PharmaDrug Collaborates with PharmaTher for Development of DMT Transdermal Patch

Newsfile February 22, 2023

PharmaDrug Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

Newsfile February 13, 2023

PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer

Newsfile January 31, 2023

PharmaDrug (CSE:PHRX) advances cancer fighting drug

Caroline Egan  October 4, 2022

PharmaDrug Advances Programs in Oncology and Infectious Disease Through Completion of cGMP Drug Substance Manufacturing

Newsfile October 4, 2022

PharmaDrug (CSE:PHRX) advances DMT program

Caroline Egan  August 25, 2022